These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38278100)

  • 1. Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants.
    Zhang Z; Xu L; Wang X; Kong L; Shi Z; Zhong Q; Xu Y; Wang J
    Tuberculosis (Edinb); 2024 Mar; 145():102480. PubMed ID: 38278100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity.
    Shi Z; Zhou L; Wang X; Zhang Z; Kong L; Zhang Y
    Arch Microbiol; 2024 Jul; 206(8):352. PubMed ID: 39012499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and expression of Mycobacterium tuberculosis fusion protein AR2 and its immunogenicity in combination with various adjuvants to form vaccine.
    Wang X; Du J; Zhang Y; Zhu T; Mao L; Xu L; Shi Z; Zhang J; Sun Q; Qi Z; Xia L
    Tuberculosis (Edinb); 2022 Dec; 137():102270. PubMed ID: 36265370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster.
    Mao L; Xu L; Wang X; Xing Y; Wang J; Zhang Y; Yuan W; Du J; Shi Z; Ma J; Zhang J; Zhang X; Wang X
    Tuberculosis (Edinb); 2022 May; 134():102186. PubMed ID: 35245739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation.
    Ma J; Teng X; Wang X; Fan X; Wu Y; Tian M; Zhou Z; Li L
    EBioMedicine; 2017 Aug; 22():143-154. PubMed ID: 28711483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Immunogenicity and
    Mao LR; Du JP; Wang XC; Xu LF; Zhang YP; Sun QS; Shi ZL; Xing YR; Su YX; Wang SJ; Wang J; Ma JL; Zhang JY
    ACS Infect Dis; 2023 Mar; 9(3):593-608. PubMed ID: 36808986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.
    Ma J; Tian M; Fan X; Yu Q; Jing Y; Wang W; Li L; Zhou Z
    Oncotarget; 2016 Sep; 7(39):63804-63815. PubMed ID: 27566581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and Protective Efficacy of a Fusion Protein Tuberculosis Vaccine Combining Five Esx Family Proteins.
    Xiang ZH; Sun RF; Lin C; Chen FZ; Mai JT; Liu YX; Xu ZY; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():226. PubMed ID: 28620588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
    Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
    Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
    Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
    J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary evaluation of immunogenicity and protective effect of multicomponent recombinant protein vaccine EPRHP014 against tuberculosis].
    Cao B; Fan XT; Wang RH; Luan XL; Qian CY; Yu JJ; Liu HC; Li MC; Li GL; Zhao XQ; Yuan XQ; Wan KL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Oct; 44(10):1653-1660. PubMed ID: 37875456
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
    Billeskov R; Christensen JP; Aagaard C; Andersen P; Dietrich J
    PLoS One; 2013; 8(8):e72185. PubMed ID: 23977248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological characterization of chimeras of high specificity antigens from Mycobacterium tuberculosis H37Rv.
    Fatma F; Tripathi DK; Srivastava M; Srivastava KK; Arora A
    Tuberculosis (Edinb); 2021 Mar; 127():102054. PubMed ID: 33550109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.